Literature DB >> 545867

The clinical physiology of water metabolism. Part II: Renal mechanisms for urinary concentration; diabetes insipidus.

R E Weitzman, C R Kleeman.   

Abstract

The renal reabsorption of water independent of solute is the result of the coordinated function of the collecting duct and the ascending limb of the loop of Henle. The unique juxtaposition of the ascending and descending portions of the loop of Henle and of the vasa recta permits the function of a counter-current multiplier system in which water is removed from the tubular lumen and reabsorbed into the circulation. The driving force for reabsorption is the osmotic gradient in the renal medulla which is dependent, in part, on chloride (followed by sodium) pumping from the thick ascending loop of Henle. Urea trapping is also thought to play an important role in the generation of a hypertonic medullary interstitium. Arginine vasopressin (AVP) acts by binding to receptors on the cell membrane and activating adenylate cyclase. This, inturn, results in the intracellular accumulation of cyclic adenosine monophosphate (AMP) which in some fashion abruptly increases the water permeability of the luminal membrane of cells in the collecting duct. As a consequence, water flows along an osmotic gradient out of the tubular lumen into the medullary interstitium. Diabetes insipidus is the clinical condition associated with either a deficiency of or a resistance to AVP. Central diabetes insipidus is due to diminished release of AVP following damage to either the neurosecretory nuclei or the pituitary stalk. Possible causes include idiopathic, familial, trauma, tumor, infection or vascular lesions. Patients present with polyuria, usually beginning over a period of a few days. The diagnosis is made by showing that urinary concentration is impaired after water restriction but that there is a good response to exogenous vasopressin therapy. Nephrogenic diabetes insipidus can be identified by a patient's lack of response to AVP. Nephrogenic diabetes insipidus is caused by a familial defect, although milder forms can be acquired as a result of various forms of renal disease. Central diabetes insipidus is eminently responsive to replacement therapy, particularly with dDAVP, a long lasting analogue of AVP. Nephrogenic diabetes insipidus is best treated with a combination of thiazide diuretics as well as a diet low in sodium and protein.

Entities:  

Mesh:

Year:  1979        PMID: 545867      PMCID: PMC1271910     

Source DB:  PubMed          Journal:  West J Med        ISSN: 0093-0415


  78 in total

1.  Chlorpropamide treatment of diabetes insipidus in children.

Authors:  H L Vallet; M Prasad; R B Goldbloom
Journal:  Pediatrics       Date:  1970-02       Impact factor: 7.124

2.  Potentiation of the antidiuretic effect of vasopressin by chlorpropamide.

Authors:  W O Berndt; M Miller; W M Kettyle; H Valtin
Journal:  Endocrinology       Date:  1970-05       Impact factor: 4.736

3.  Recognition of partial defects in antidiuretic hormone secretion.

Authors:  M Miller; T Dalakos; A M Moses; H Fellerman; D H Streeten
Journal:  Ann Intern Med       Date:  1970-11       Impact factor: 25.391

4.  Hyponatremia due to sulfonylurea compounds.

Authors:  G A Hagen; T F Frawley
Journal:  J Clin Endocrinol Metab       Date:  1970-11       Impact factor: 5.958

5.  Treatment of vasopressin-sensitive diabetes insipidus with chlorpropamide.

Authors:  R H Kunstadter; E C Cabana; W Oh
Journal:  Am J Dis Child       Date:  1969-04

6.  Chronic sustained hypernatremia and hypovolemia in hypothalamic tumor. A physiologic study.

Authors:  A Vejjajiva; V Sitprija; S Shuangshoti
Journal:  Neurology       Date:  1969-02       Impact factor: 9.910

7.  Radioimmunoassay of arginine vasopressin in human plasma.

Authors:  C G Beardwell
Journal:  J Clin Endocrinol Metab       Date:  1971-08       Impact factor: 5.958

8.  Functional characteristics of the diluting segment of the dog nephron and the effect of extracellular volume expansion on its reabsorptive capacity.

Authors:  G Eknoyan; W N Suki; F C Rector; D W Seldin
Journal:  J Clin Invest       Date:  1967-07       Impact factor: 14.808

9.  [Preliminary study of antidiuretic effect of clofibrate (or atromid S) in pitressosensitive diabetes insipidus].

Authors:  J L de Gennes; C Bertrand; B Bigorie; J Truffert
Journal:  Ann Endocrinol (Paris)       Date:  1970 Mar-Apr       Impact factor: 2.478

10.  Antidiuretic effect of 1-propyl-3-p-chlorobenzene-sulfonylurea (chlorpropamide).

Authors:  J Reforzo-Membrives; L I Moledo; A E Lanaro; A Megías
Journal:  J Clin Endocrinol Metab       Date:  1968-03       Impact factor: 5.958

View more
  3 in total

Review 1.  Familial forms of diabetes insipidus: clinical and molecular characteristics.

Authors:  Muriel Babey; Peter Kopp; Gary L Robertson
Journal:  Nat Rev Endocrinol       Date:  2011-07-05       Impact factor: 43.330

Review 2.  Key to Opening Kidney for In Vitro-In Vivo Extrapolation Entrance in Health and Disease: Part I: In Vitro Systems and Physiological Data.

Authors:  Daniel Scotcher; Christopher Jones; Maria Posada; Amin Rostami-Hodjegan; Aleksandra Galetin
Journal:  AAPS J       Date:  2016-06-30       Impact factor: 4.009

Review 3.  Diabetes insipidus. Current treatment recommendations.

Authors:  J R Seckl; D B Dunger
Journal:  Drugs       Date:  1992-08       Impact factor: 9.546

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.